Lower Distending Pressure Improves Respiratory Mechanics in Congenital Diaphragmatic Hernia Complicated by Persistent

David Guevorkian1, Sebastien Mur2, Eric Cavatorta3

  • 1Neonatal Intensive Care, Department of Neonatology, Marie Curie Public Hospital, Charleroi, Belgium; Department of Neonatology, Jeanne de Flandre Hospital, University Hospital of Lille, F-59000 France.

Insights

Lower distending pressures improve respiratory mechanics and pulmonary circulation in newborns with congenital diaphragmatic hernia (CDH) and persistent pulmonary hypertension (PPHN). This suggests CDH lungs may be prone to overdistension.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pulmonology
  • Critical Care

Background:

  • Congenital diaphragmatic hernia (CDH) often leads to persistent pulmonary hypertension (PPHN) in newborns.
  • Understanding optimal ventilatory strategies is crucial for managing these complex conditions.

Purpose of the Study:

  • To evaluate the impact of different positive end-expiratory pressure (PEEP) levels on respiratory mechanics and pulmonary circulation in infants with CDH and PPHN.

Main Methods:

  • A prospective, randomized, crossover pilot study involving 17 infants with CDH and PPHN.
  • Infants received 2 cmH2O and 5 cmH2O of PEEP in a crossover design.
  • Respiratory mechanics, lung function, and hemodynamic variables were assessed using Doppler echocardiography.

Main Results:

  • Lower PEEP (2 cmH2O) resulted in greater tidal volume, minute ventilation, and respiratory system compliance compared to higher PEEP (5 cmH2O).
  • Lower PEEP reduced PaCO2 and ventilation index, and improved postductal oxygen saturation.
  • Hemodynamic parameters, including left ventricle diameter and pulmonary blood flow, were more favorable at lower PEEP levels.

Conclusions:

  • Lower distending pressures are associated with improved respiratory mechanics in infants with mild-to-moderate CDH post-repair.
  • Hypoplastic lungs in CDH may be susceptible to overdistension, indicating a need for careful pressure management.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
633
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
664
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.5K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
619
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
479